glp 1 agonists vs sglt2 inhibitors GLP-1 vs. Inhibitors: Best Practices for Type 2 Diabetes Care SGLTi and GLP-1 in HF

TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

However, we were unable to achieve satisfactory staining of human sections with other commercially available antibodies that mark ferroptosis, including 4HNE (4-hydroxynonenal) and anti-monoaldehyde (MDA)

doi: 10.1007/BF02543026

In contrast, the symmetric proliferation of medium-sized to large epitheloid or spindle-shaped melanocytes with retraction artefact (clefting), Kamino bodies, and dermal maturation without cellular or nuclear pleomorphism suggest acral spitz nevus